Published in Health Business Week, August 20th, 2004
The company reported a loss from continuing operations of $169 million, or $0.28 per diluted share, which includes after-tax charges of $414 million, or $0.68 per diluted share related to the 2004 restructuring initiatives and other items.
Excluding these special charges, earnings from continuing operations totaled $245 million, or $0.40 per diluted share, which is within the range of the company's previous guidance for the quarter of $0.37 to $0.41 per diluted share.
Given the company's announced plans to restate its financial results, all...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.